Sodium oxybate in the treatment of alcohol withdrawal syndrome: A randomized double-blind comparative study versus oxazepam. the gate 1 trial

CNS Drugs

Volumn 28, Issue 8, 2014, Pages 743-752

  Caputo, Fabio ^a,b   Skala, Katrin ^c   Mirijello, Antonio ^d   Ferrulli, Anna ^d   Walter, Henriette ^c   Lesch, Otto ^c   Addolorato, Giovanni ^d  

^a SS Annunziata Hospital   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OXAZEPAM; OXYBATE SODIUM; PLACEBO;

ADULT; AGED; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BREATH ANALYSIS; BRONCHITIS; CLINICAL ASSESSMENT TOOL; CLINICAL INSTITUTE WITHDRAWAL ASSESSMENT FOR ALCOHOL REVISED SCALE; COMPARATIVE STUDY; CONTROLLED STUDY; DELIRIUM TREMENS; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; GOLD STANDARD; GOUT; HUMAN; HYPERTENSION; HYPOMANIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MUSCLE ATROPHY; PERIODONTAL DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SLEEP DISORDER; SOMNOLENCE; SWEATING; TACHYCARDIA; TREATMENT DURATION; TREMOR; VIRUS INFECTION; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY; PHASE 4 CLINICAL TRIAL; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; ALCOHOLISM; ANXIETY; CRAVING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OXAZEPAM; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SODIUM OXYBATE; SUBSTANCE WITHDRAWAL SYNDROME; SWEATING; TREATMENT OUTCOME; TREMOR;

EID: 84905560288     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0183-1     Document Type: Article

References (33)

1. Schuckit MA. Alcohol-use disorders. Lancet. 2009;373:492-501.
2. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373:2223-33.
3. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst Rev. 2011;6:CD008537.
4. Tan KR, Brown M, Labouèbe G, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463:769-74.
5. Addolorato G, Leggio L, Hopf FW, Diana M, Bonci A. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology. 2012;37:163-77.
6. Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1106-17.
7. Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM. Double blind controlled trial of γ-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2002;37:67-73.
8. Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25:1324-9.
9. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med. 2006;119(276):e13-8.
10. Skala K, Caputo F, Mirijello A, et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother. 2014;15:245-57.
11. Keating GM. Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin Drug Investig. 2014;34:63-80.
12. Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010;2:CD006266.
13. Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med. 2005;352:2721-32.
14. Gessa GL, Agabio R, Carai MA, et al. Mechanism of the antialcohol effect of gamma-hydroxybutyric acid. Alcohol. 2000;20:271-6.
15. Bay T, Eghorn LF, Klein AB, Wellendorph P. GHB receptor targets in the CNS: focus on high-affinity binding sites. Biochem Pharmacol. 2014;87:220-8.
16. Addolorato G, Balducci G, Capristo E, et al. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol Clin Exp Res. 1999;23:1596-604.
17. Nava F, Premi S, Manzato, et al. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam. Am J Drug Alcohol Abuse 2007;33:379-92.
18. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 4th edn (text revision). Washington: American Psychiatric Press, 2000.
19. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353-7.
20. Veltrup C. "Craving" bei Alkoholabhängingen (Lübecker Craving-Risiko-Rückfall-Fragebogen). Wien Klin Wochenschr. 1994;106:75-9.
21. Walter H, Hertling I, Benda N, et al. Sensitivity and specificity of carbohydrate-deficient transferrin in drinking experiments and different patients. Alcohol. 2001;25:189-94.
22. Pelc I. The Plinius Major Society. Alcohol Alcohol Suppl. 1993;2:119-20.
23. Schlaff G, Walter H, Lesch OM. The Lesch alcoholism typology - psychiatric and psychosocial treatment approaches. Ann Gastroenterol. 2011;24:89-97.
24. Snead OC 3rd, Nichols AC. Gamma-hydroxybutyric acid binding sites: evidence for coupling to a chloride anion channel. Neuropharmacology. 1987;26:1519-23.
25. Zielmann SL, Petrow H, Walther P, Henze T. Intensive care of delirium syndromes. Anaesthesiol Reanim. 2003;28:8-12.
26. Smink BE, Hofman BJ, Dijkhuizen A, et al. The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam. Br J Clin Pharmacol. 2008;66:556-60.
27. Carter LP, Griffiths RR, Mintzer MZ. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl). 2009;206:141-54.
28. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila). 2012;50:458-70.
29. Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 γ-hydroxybutyrate associated deaths: lethal toxicity and trauma. Am J Emerg Med. 2011;29:319-32.
30. Jones AW, Holmegren A, Halner J. Toxicological analysis of blood and urine samples from female victims of alleged sexual assault. Clin Toxicol. 2012;50:555-61.
31. Németh Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol. 2010;24:1281-7.
32. Gonzalez A, Nutt DJ. Gamma-hydroxybutyrate abuse and dependency. J Psychopharmacol. 2005;19:195-204.
33. Addolorato G, Leggio L, Ferrulli A, Caputo F, Gasbarrini A. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs. 2009;18:675-86.